Most Read Articles
Audrey Abella, 26 Jul 2017
Upstream use of the P2Y12 receptor antagonist ticagrelor provides benefit over clopidogrel in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) with a relatively rapid time to angiography, according to a post hoc analysis of the PLATO* trial.
11 Oct 2018
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.

Bisphosphonate ‘holiday’ tied to increased fracture risk

Roshini Claire Anthony
10 Nov 2017

Women who temporarily or permanently stop taking bisphosphonates (drug holiday) for an extended period of time may have an increased risk of hip fractures, findings from a recent population-based study revealed.

“[A] bisphosphonate drug holiday greater than 2 years was associated with a significantly increased risk for hip fracture of up to 39 percent compared with continued bisphosphonate use,” said study lead author Professor Jeffrey Curtis who presented the findings at the annual meeting of the ACR/ARHP* held in San Diego, California, US, on behalf of himself and his fellow investigators from the University of Alabama at Birmingham, Alabama, US.

Compared with current users (crude incidence rate, 9.6 per 1,000 person-years), women who had ceased bisphosphonate therapy for more than 2 and up to 3 years had the highest rate of fracture incidence (crude incidence rate, 15.7 per 1,000 person-years; adjusted hazard ratio [adjHR], 1.39). [ACR/ARHP 2017, abstract 828]

Women who had ceased bisphosphonate therapy for >0 to ≤3 months, >3 months to ≤1 year, and >1 to ≤2 years also had an increased risk of hip fracture (adjHR, 1.29, 1.12, and 1.21, respectively; crude incidence rate, 13.1, 12.0, and 13.3 per 1,000 person-years, respectively).

Using Medicare data from 2006 to 2014, researchers identified 156,236 women (mean age, 78.5 years) who were long-term users of bisphosphonate therapy and were ≥80 percent treatment-adherent for ≥3 years at baseline. Patients who used other bone therapies such as denosumab, oestrogen, calcitonin, or teriparatide were excluded.

Over a median 2.1-year follow-up period, 40.1 percent (n=62,676) of patients ceased bisphosphonate therapy for ≥6 months, 12.7 percent (n=7,947) of whom later restarted bisphosphonate therapy. There were 3,745 hip fractures reported during the follow-up period.

Hip fracture incidence was lowest among women currently on bisphosphonate therapy and increased with longer duration of drug holiday.

“Given FDA** warnings, drug holidays [temporary or permanent discontinuation] of bisphosphonates after long-term [3–5 years] continuous therapy is becoming increasingly common in the US,” said Curtis and colleagues.

“Our goal was to evaluate the risk of discontinuing therapy based on the length of the holiday, controlling for any possibly confounding factors, such as race, median income, rural or urban location, DXA scores, or comorbidities,” said Curtis.

“While the notion of a drug holiday has become commonplace in osteoporosis management, there’s a dearth of evidence on when we should consider restarting bisphosphonate therapy. The study’s findings may provide useful evidence to help guide rheumatologists as they plan long-term therapy for their patients dealing with low bone mass,” he added.  

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 26 Jul 2017
Upstream use of the P2Y12 receptor antagonist ticagrelor provides benefit over clopidogrel in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) with a relatively rapid time to angiography, according to a post hoc analysis of the PLATO* trial.
11 Oct 2018
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.